BAVA.CO Stock - Bavarian Nordic A/S
Unlock GoAI Insights for BAVA.CO
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $5.72B | $7.06B | $3.15B | $1.90B | $1.85B |
| Gross Profit | $2.82B | $4.53B | $1.70B | $570.32M | $657.29M |
| Gross Margin | 49.3% | 64.1% | 54.0% | 30.1% | 35.5% |
| Operating Income | $939.77M | $1.50B | $-3,845,000 | $-263,314,000 | $449.62M |
| Net Income | $987.98M | $1.48B | $-347,382,000 | $-464,775,000 | $277.52M |
| Net Margin | 17.3% | 20.9% | -11.0% | -24.5% | 15.0% |
| EPS | $12.61 | $19.23 | $-4.93 | $-7.37 | $5.13 |
Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN (freeze-dried) that has completed Phase III clinical trials for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase II clinical trial for the treatment of SARS-CoV-2; and TAEK-VAC, which is in Phase I/II clinical trial for treatment of advanced HER2 and brachyury-expressing cancers. It has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. It operates in the United States, Germany, Belgium, France, Canada, the United Kingdom, Hong Kong, Saudi Arabia, Australia, Switzerland, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.
Visit WebsiteEarnings History & Surprises
BAVA.COEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 7, 2026 | — | — | — | — |
Q1 2026 | Mar 3, 2026 | — | — | — | — |
Q4 2025 | Nov 14, 2025 | $1.90 | $13.70 | +621.1% | ✓ BEAT |
Q3 2025 | Aug 22, 2025 | $1.90 | $4.50 | +136.8% | ✓ BEAT |
Q2 2025 | May 8, 2025 | — | $2.70 | — | — |
Q1 2025 | Mar 5, 2025 | $8.56 | $9.81 | +14.6% | ✓ BEAT |
Q4 2024 | Nov 15, 2024 | $5.50 | $2.54 | -53.8% | ✗ MISS |
Q3 2024 | Aug 22, 2024 | $1.90 | $3.30 | +73.7% | ✓ BEAT |
Q2 2024 | May 8, 2024 | $1.90 | $-1.50 | -178.9% | ✗ MISS |
Q1 2024 | Mar 6, 2024 | $7.80 | $11.70 | +50.0% | ✓ BEAT |
Q4 2023 | Nov 16, 2023 | $6.43 | $-4.40 | -168.4% | ✗ MISS |
Q3 2023 | Aug 23, 2023 | $3.95 | $7.10 | +79.7% | ✓ BEAT |
Q2 2023 | May 9, 2023 | $2.38 | $5.10 | +114.3% | ✓ BEAT |
Q1 2023 | Mar 2, 2023 | $3.65 | $2.20 | -39.7% | ✗ MISS |
Q4 2022 | Nov 9, 2022 | $-0.47 | $0.20 | +142.6% | ✓ BEAT |
Q3 2022 | Aug 24, 2022 | $-4.05 | $-3.40 | +16.0% | ✓ BEAT |
Q2 2022 | May 9, 2022 | $-4.46 | $-3.90 | +12.6% | ✓ BEAT |
Q1 2022 | Mar 4, 2022 | $-0.31 | $-1.60 | -416.1% | ✗ MISS |
Q4 2021 | Nov 12, 2021 | $-1.04 | $-1.30 | -25.0% | ✗ MISS |
Q3 2021 | Aug 25, 2021 | $0.24 | $-2.40 | -1100.0% | ✗ MISS |
Latest News
Frequently Asked Questions about BAVA.CO
What is BAVA.CO's current stock price?
What is the analyst price target for BAVA.CO?
What sector is Bavarian Nordic A/S in?
What is BAVA.CO's market cap?
Does BAVA.CO pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to BAVA.CO for comparison